Angiosarcoma

Diakonos Oncology CFO Anthony Baldor to Provide Corporate Update at BIO International Convention In San Diego, June 3 - 6, 2024

Retrieved on: 
月曜日, 6月 3, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, San Diego Convention Center, GBM, Glioblastoma, Angiosarcoma, Patient, Cancer, Pancreatic cancer, TH1, Immune system, Survival, Growth

Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced today that Chief Financial Officer and Head Of Business Development Anthony Baldor will give a company presentation at the 2024 BIO International Convention June 3 – 6, 2024 in San Diego.

Key Points: 
  • Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced today that Chief Financial Officer and Head Of Business Development Anthony Baldor will give a company presentation at the 2024 BIO International Convention June 3 – 6, 2024 in San Diego.
  • The corporate update will be June 4 at 3 pm PT in Company Presentation Theater 2 at the San Diego Convention Center.
  • Diakonos recently completed a Phase 1 trial of DOC1021, its lead vaccine for glioblastoma multiforme (GBM), and is planning a Phase 2 study.
  • “We are very excited about the results of our Phase 1 trial for GBM,” Mr. Baldor said.

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Patient, Leiomyosarcoma, NK, Clinical trial, Male, Trial of the century, Neurodegenerative disease, Safety, CD16, MD, Cancer, NCR1, IP, Angiosarcoma, Fatigue, Society, Aes, NKG2D, Pharmaceutical industry

SANTA ANA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced an online publication, titled “Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion” at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Key Points: 
  • SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.
  • This Phase 1 clinical trial is a multi-center, open-label study evaluating the safety and tolerability of SNK02 in participants with pathologically confirmed solid tumors refractory to standard of care therapy.
  • SNK02 was administered as an intravenous infusion (IV), weekly for eight weeks in patients with advanced solid tumors.
  • SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.

Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma

Retrieved on: 
火曜日, 4月 9, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SOC, Survival, IDH, Patient, GBM, RNA, Protein, AACR, Pancreatic cancer, Neoplasm, Prognosis, Poster, Vaccine, FDA, Angiosarcoma, Pharmaceutical industry

Twelve of 16 patients with newly diagnosed GBM remain alive with no serious adverse events attributable to DOC1021.

Key Points: 
  • Twelve of 16 patients with newly diagnosed GBM remain alive with no serious adverse events attributable to DOC1021.
  • “These very encouraging results support our confidence in the potential for our dendritic cell vaccines to significantly improve the lives of patients with the most deadly cancers,” said Mike Wicks, Diakonos CEO.
  • Despite their challenging prognosis, these patients saw a statistically significant improvement in expected overall survival of 7.7 months for similar patients.
  • Diakonos’ dendritic cell vaccines are made with a patient’s own immune cells combined with RNA and proteins prepared from a sample of their tumor.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 2月 8, 2024
Carcinoma, Neoplasm, Melanoma, NMSC, Merkel-cell carcinoma, REPL, Angiosarcoma, SITC, PFS, Clinical trial, Research, RECIST, Society, Hercules, Patient, CSCC, Type, FDA, Marketing, Investment, RP1, Food, MCC, Immunotherapy, Skin, Nivolumab, Uveal melanoma, Annual general meeting, BLA, RP2, Pharmaceutical industry

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.

Key Points: 
  • WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
  • We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024.
  • Selling, general and administrative expenses included $4.5 million in stock-based compensation expenses for the third quarter ended December 31, 2023.
  • Net Loss: Net loss was $51.1 million for the third quarter ended December 31, 2023, as compared to a net loss of $39.7 million for the third quarter ended December 31, 2022.

Diakonos Oncology Completes Phase 1 Glioblastoma Trial Recruitment; Receives FDA Orphan Drug Designation

Retrieved on: 
火曜日, 1月 2, 2024
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Marketing, Food, Neoplasm, B cell, Glioma, Vaccine, Person, Incidence, Doctor of Philosophy, Recurrence, Orphan drug, Pancreatic cancer, Glioblastoma, GBM, Patient, Angiosarcoma, Safety, Pharmaceutical industry

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM).

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM).
  • With the first patient enrolled in October 2021, DOC1021 has been administered to 16 patients across four dose levels.
  • To date, DOC1021 appears to be very safe and well tolerated as there have been no attributable serious adverse events observed from DOC1021.
  • In addition to the Phase 1 trial of DOC1021 for GBM ( NCT04552886 ), the company has two other vaccines in clinical development for pancreatic cancer ( NCT04157127 ) and angiosarcoma ( NCT05799612 ).

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Retrieved on: 
火曜日, 12月 5, 2023
Chills, CRS, Melanoma, RP1, CRC, Food, Melanoma Research, RECIST, NMSC, Transplant, Diarrhea, FDA, Cytokine release syndrome, Colorectal cancer, SCCHN, Type, RP3, CRR, Fatigue, Headache, Nausea, Itch, Myocarditis, Incidence, Nivolumab, Influenza-like illness, Research, Clinical trial, Injection site reaction, Myalgia, CSCC, Skin cancer, HCC, Weakness, Society, Head, Appetite, RP2, Regeneron Pharmaceuticals, Carcinoma, Investment, Webcast, Patient, Lipase, Angiosarcoma, MCC, Vomiting, Neck, Uveal melanoma, Rash, BLA, Pharmaceutical industry

The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.

Key Points: 
  • The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
  • The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
  • The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.

Diakonos Oncology Names Ian H. Bellayr, Ph.D. Chief Regulatory Officer

Retrieved on: 
月曜日, 11月 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Pancreatic cancer, Immune system, University, Food, Gene, Angiosarcoma, Glioblastoma, Biological engineering, Patient, DOC, Element, Division, FDA, Vaccine, Infection, Biomedicine, Kidney, National Institutes of Health, NIH, B cell, Recurrence, Neoplasm, Bangladesh Technical Education Board, Digestive, Biomedical engineering, Injection, Pharmaceutical industry

Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that Ian H. Bellayr, Ph.D., a regulatory expert with the U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH), has joined the company as its Chief Regulatory Officer.

Key Points: 
  • Diakonos Oncology Corporation (“Diakonos”), a clinical stage immuno-oncology company, announced today that Ian H. Bellayr, Ph.D., a regulatory expert with the U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH), has joined the company as its Chief Regulatory Officer.
  • Bellayr's regulatory expertise arrives at a crucial time for Diakonos as we conclude our Phase 1 glioblastoma trial,” said Mike Wicks, Chief Executive Officer of Diakonos.
  • “Diakonos has a unique technology that allows for a personalized cell therapy that is unbiased in its potential to effectively treat multiple indications.
  • Diakonos’ lead dendritic cell vaccine, DOC 1021, is in Phase 1 trials in the U.S. for glioblastoma ( NCT04552886 ).

Angiosarcoma Patient Celebrates 7-Year Remission with Pioneering Use of PD-1 Inhibitor: Every Cure Unleashes AI to Ensure No Treatment is Left Overlooked

Retrieved on: 
水曜日, 8月 2, 2023
University, Cancer, PET, Prognosis, National Comprehensive Cancer Network, Organization, Patient, Standard of care, Algorithm, David Fajgenbaum, Artificial intelligence, Diagnosis, PD-1, FDA, Pembrolizumab, Health, PD-L1, Disease, Pharmaceutical industry, Medical device, Angiosarcoma

PHILADELPHIA, Aug. 2, 2023 /PRNewswire/ -- A patient cured of angiosarcoma from a pioneering use of a repurposed PD-1 inhibitor is celebrating seven years of remission after the treatment was hidden in the medical literature before being discovered by Every Cure Co-founder Dr. David Fajgenbaum and his team at the University of Pennsylvania. Every Cure and its partners are developing medical databases and AI algorithms to ensure no potential cure remains overlooked among the vast number of medical studies.

Key Points: 
  • Every Cure and its partners are building on this breakthrough, deploying innovative AI algorithms that evaluate the potential of every drug for every disease.
  • Every Cure and its partners are developing medical databases and AI algorithms to ensure no potential cure remains overlooked among the vast number of medical studies.
  • In 2016, Michael was confronted with a diagnosis of metastatic angiosarcoma and given a prognosis of just three months.
  • Every Cure is committed to ensuring no potential cure remains overlooked in the vast number of medical studies performed each year.

First Life Saved with AI-Discovered Repurposed Medicine for Castleman Disease with Significant Potential Applications to Treat Other Illnesses

Retrieved on: 
木曜日, 7月 13, 2023
Storm, Pennsylvania State University, University, Argyreia nervosa, Spectrum, Food, COVID-19, Adalimumab, Hope, Organ dysfunction, Research, University of North Carolina at Greensboro, Idiopathic multicentric Castleman disease, Sepsis, Dassault Group, Hospice, Crohn's disease, Duct (flow), Juvenile idiopathic arthritis, Publication, Castleman, Castleman disease, Patient, Castleman Disease Collaborative Network, Algorithm, Immune system, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ALS, Family, Skin, Rheumatoid arthritis, Disease, Medical device, Pharmaceutical industry, Angiosarcoma, Medidata Solutions

PHILADELPHIA, July 13, 2023 /PRNewswire/ -- A patient's life was saved after researchers at the University of Pennsylvania, Castleman Disease Collaborative Network, Medidata, a Dassault Systèmes company, and Every Cure, led by Dr. David Fajgenbaum, utilized AI to uncover a previously unknown use for an existing drug, adalimumab, to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to unlock new uses for existing medicines across all diseases, and the latest scoring identified adalimumab as the most promising treatment for iMCD out of all 3,000 approved drugs.

Key Points: 
  • Every Cure and its partners are expanding upon this discovery to harness a novel AI algorithm that calculates the potential use of every drug to treat every disease.
  • iMCD is a rare and life-threatening disorder that involves hyperactivation of the body's immune system which causes uncontrolled organ dysfunction.
  • The only FDA-approved treatment works in a portion of those diagnosed with iMCD, leaving the majority of patients with limited options.
  • The algorithm scores every existing drug's potential to treat every known disease based on worldwide knowledge from publications and databases.

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

Retrieved on: 
木曜日, 11月 17, 2022
University of Colorado School of Medicine, Anschutz Medical Campus, Infection, Immune system, University, Clinical research, Therapy, Patient, Biomarker, Annual report, Mink, Annual general meeting, GMP, Security (finance), Liposarcoma, Cancer, Risk, Research, Sarcoma, Immunotherapy, Hospital, Pharmaceutical industry, Medical imaging, Vaccine, Agenus, MD, Angiosarcoma

The results will be presented tomorrow in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting in Vancouver, BC, Canada.

Key Points: 
  • The results will be presented tomorrow in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting in Vancouver, BC, Canada.
  • The superior efficacy and durable responses achieved with botensilimab and balstilimab in advanced sarcoma build on the unprecedented clinical responses we have observed with this combination in multiple cold, treatment-resistant cancers, said Steven ODay, MD, Chief Medical Officer at Agenus.
  • A total of 13 evaluable patients with advanced sarcoma received either 1 or 2 mg/kg botensilimab every 6 weeks and 3 mg/kg balstilimab every 2 weeks.
  • The clinical responses demonstrated by botensilimab and balstilimab in this study are compelling and support plans for further development of this combination in sarcoma.